Stand Up To Cancer Canada will support two, four-year cancer research dream teams with nearly $20 million USD raised by SU2C Canada collaborators and from the charity's September telecast. The dream teams will focus their research on translational research in breast cancer and cancer stem cells.
FDA approved bortezomib (Velcade) injection for previously untreated patients with mantle cell lymphoma.
FDA granted priority review to the investigational bispecific T-cell engager antibody construct blinatumomab for the treatment of adults with Philadelphia-negative relapsed/refractory B-precursor acute lymphoblastic leukemia.\
FDA granted priority review status to lenvatinib mesylate as a treatment for progressive radioactive iodine-refractory differentiated thyroid cancer.
FRANCIS GILES was named deputy director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
CANCER TREATMENT CENTERS OF AMERICA launched a fertility preservation program, OncoPrez, at its hospitals in Chicago, Philadelphia and Tulsa.
THE INDIANA UNIVERSITY Melvin and Bren Simon Cancer Center was recognized by NCI as a designated cancer center, and had their support grant increased by 20 percent, following an in-depth peer review.
ZHU CHEN was honored by the American Association for Cancer Research with its Award for Distinguished Public Service and Global Impact in Cancer Research in Biomedical Science.
LILI YANG received the $2.3 million Director's New Innovator Award from NIH for research into developing ways to genetically program blood stem cells to attack cancers. Yang is an assistant professor of microbiology, immunology and molecular genetics at UCLA Jonsson Comprehensive Cancer Center.
The fourth edition of the European Code Against Cancer was published by the International Agency for Research on Cancer, with the participation of the European Commission.
